What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes

galapagos lizard

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*
This field is for validation purposes and should be left unchanged.

Monday: AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)


Tuesday: Will Roche lose it’s Worldwide Leading position in Cancer treatments?


Wednesday: CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?


Thursday: Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government


Friday: Merck relinquishes Rare Disease license to instead focus on Immuno-oncology


Weekend: We will celebrate German unity on Saturday.

reichstag-324982_1280

Explore other topics: AbbVieCRISPRGalapagosMerckRoche